Scandion Oncology - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Centaur Media

MCap

GBP36m

Last close

GBP0.27

▲ 3.50 (14.89%)

IRLAB Therapeutics

MCap

SEK482m

Last close

SEK10.15

▲ 0.85 (9.14%)

OpGen

MCap

USD9m

Last close

USD0.86

▲ 0.06 (7.50%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Overview
Research
Thematics

Latest Insights

View More

Healthcare |
Update

30.05.23

Scandion Oncology — An active quarter with AML plans in the mix

Flash note

03.04.23

Scandion Oncology — PANTAX Phase I trial meets primary endpoint

Healthcare |
Flash note

29.03.23

Scandion Oncology — Expanding SCO-101 into AML

Healthcare |
Update

24.02.23

Scandion Oncology — A defining year ahead for SCO-101

Flash note

Healthcare

17.08.22

Scandion Oncology — PANTAX dosing schedule expanded

Flash note

Healthcare

05.07.22

Scandion Oncology — Outcome of rights issue

Initiation

Healthcare

17.06.22

Scandion Oncology — Chemotherapy overcoming drug resistance

edison tv

Healthcare

09.02.22

Scandion Oncology: Edison Open House Healthcare 2022

QuickView

Healthcare

14.01.22

Scandion Oncology — Drug-resistant cancer solutions